SLC5A2 and cardiovascular disorder: However, in patients with established cardiovascular disease and with several risk factors, the European Cardiovascular Society guidelines recommend the introduction of SGLT-2 inhibitors as first-line treatment, although, in most cases, RCT patients were treated with metformin in the first line [2].